A phase Ib/IIa study to access safety and efficacy of the combination therapy of GX-188E and Pembrolizumab for the treatment of patients with Human papillomavirus-induced cancers

Trial Profile

A phase Ib/IIa study to access safety and efficacy of the combination therapy of GX-188E and Pembrolizumab for the treatment of patients with Human papillomavirus-induced cancers

Planning
Phase of Trial: Phase I/II

Latest Information Update: 19 Jun 2017

At a glance

  • Drugs GX 188E (Primary) ; Pembrolizumab (Primary)
  • Indications Cervical cancer
  • Focus Adverse reactions
  • Sponsors Genexine
  • Most Recent Events

    • 19 Jun 2017 According to a Genexine media release, the Ministry of Food and Drug Safety (MFDS) in Korea has granted approval to initiate this trial.
    • 28 Nov 2016 New trial record
    • 16 Nov 2016 According to a Genexine media release, this study is scheduled to begin in the first half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top